IL-6 and IL-10 are associated with good prognosis in early stage invasive breast cancer patients

53 Background: Early-stage breast cancer patients with minimal axillary disease identified by sentinel lymph node dissection (SLND) have a low rate of regional recurrence when treated with breast conserving surgery and radiation. Patients who fit criteria for the ACOSOG Z0011 trial are candidates to avoid completion axillary lymph node dissection (CLND). As the incidence of total mastectomy (TM) has increased, it has become important to characterize which TM patients with a positive SLN may not benefit from further axillary treatment, including CLND and/or radiation therapy (XRT). Methods: We utilized an institutional database to identify patients who were treated with a TM for invasive breast cancer and had a positive SLN from 1994-2010. CLND was defined as removal of 10 or more lymph nodes. Clinicopathologic factors were analyzed and the rate of regional recurrence as well as overall and disease-free survival were determined. Results: A total of 730 patients with invasive breast cancer and a positive SLN were treated with TM including 71 patients who did not have CLND or XRT and 27 patients who did not have CLND but did receive XRT. Median follow-up was 66 months. The 10-year actuarial rate of regional recurrence was not significantly different for patients who received no further axillary treatment when compared to those who underwent CLND and XRT (4.9% vs 3.1%) or to those who underwent CLND without XRT (4.9% vs 1.4%). Survival was not significantly different between patients who did not receive further axillary treatment compared to those who underwent CLND without XRT or those who underwent both CLND and XRT. Using a nomogram previously developed by our group, the predicted probability of additional non-SLN involvement was significantly lower for patients who did not undergo CLND compared to those who did (10% vs. 23%, p<0.0001). Conclusions: In select patients with early stage breast cancer treated with mastectomy with a positive SLN, CLND may be avoided without adversely affecting recurrence or survival.

Download Full-text

Redox Protein Expression Predicts Radiotherapeutic Response in Early-Stage Invasive Breast Cancer Patients

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2010.11.002 ◽

2011 ◽

Vol 79 (5) ◽

pp. 1532-1540 ◽

Cited By ~ 17

Author(s):

Caroline M. Woolston ◽

Ahmad Al-Attar ◽

Sarah J. Storr ◽

Ian O. Ellis ◽

David A.L. Morgan ◽

...

Keyword(s):

Breast Cancer ◽

Protein Expression ◽

Cancer Patients ◽

Invasive Breast Cancer ◽

Early Stage ◽

Breast Cancer Patients ◽

Redox Protein

Download Full-text

Coordination mechanisms help hospitals improve delivery of multidisciplinary care for early-stage breast cancer patients

PsycEXTRA Dataset ◽

10.1037/e556642006-011 ◽

2002 ◽

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Early Stage ◽

Multidisciplinary Care ◽

Early Stage Breast Cancer ◽

Coordination Mechanisms ◽

Breast Cancer Patients

Download Full-text

A logistic regression nomogram to predict axillary lymph node metastasis in early invasive breast cancer patients

10.26226/morressier.5b4709836f4cb30010951a6e ◽

2018 ◽

Author(s):

Parnaz Daneshpajouhnejad

Keyword(s):

Breast Cancer ◽

Logistic Regression ◽

Lymph Node ◽

Lymph Node Metastasis ◽

Cancer Patients ◽

Invasive Breast Cancer ◽

Axillary Lymph Node Metastasis ◽

Axillary Lymph ◽

Breast Cancer Patients ◽

Node Metastasis

Download Full-text

Decision letter for "Low Z‐4OHtam concentrations are associated with adverse clinical outcome among early stage premenopausal breast cancer patients treated with adjuvant tamoxifen"

10.1002/1878-0261.12865/v1/decision1 ◽

2020 ◽

Keyword(s):

Breast Cancer ◽

Clinical Outcome ◽

Cancer Patients ◽

Early Stage ◽

Adjuvant Tamoxifen ◽

Breast Cancer Patients ◽

Adverse Clinical Outcome ◽

Premenopausal Breast Cancer

Download Full-text

Metformin improves the outcomes in Chinese invasive breast cancer patients with type 2 diabetes mellitus

Scientific Reports ◽

10.1038/s41598-021-89475-y ◽

2021 ◽

Vol 11 (1) ◽

Author(s):

Tianli Hui ◽

Chao Shang ◽

Liu Yang ◽

Meiqi Wang ◽

Ruoyang Li ◽

...

Keyword(s):

Breast Cancer ◽

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Cancer Patients ◽

Invasive Breast Cancer ◽

Breast Cancer Patients ◽

Diabetes Group ◽

Metformin Group

AbstractEarly reports indicate that metformin, a clinical drug administered to treat type 2 diabetes mellitus (T2DM), was found to be associated with a better prognosis of cancer. The objective of this study was retrospectively analyzed the effect of metformin on the outcomes of Chinese breast cancer patients with T2DM. A total of 3757 primary invasive breast cancer patients who underwent surgery from January 2010 to December 2013 were enrolled. According to the medication treatment, all the patients were divided as non-diabetes group, metformin group and insulin group. The follow-up data for disease-free survival (DFS) and overall survival (OS) were obtained from 3553 patients (median follow up of 85 months) and estimated with the Kaplan–Meier method followed by a log-rank test. Multivariate Cox proportional hazards regression model was applied. The results showed that there was a significant survival difference among non-diabetes group, metformin group and insulin group, 5-year DFS was 85.8%, 96.1%, 73.0%, and 5-year OS was 87.3%, 97.1%, 73.3% respectively (P < 0.05). Prognostic analysis showed metformin was significantly associated with better DFS and OS. Our results suggested that metformin may have a good effect on the survival of invasive breast cancer patients with T2DM.

Download Full-text